Search

everythinglearnresearchcommunity

for

Search:↓

Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.

Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.

Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.

GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.

Booster shots of mRNA vaccines for COVID-19 increased protective antibodies without worsening autoimmune skin conditions in patients.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

Immune checkpoint inhibitors can cause scalp inflammation and hair follicle issues.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Infliximab was effective in treating a scalp condition that did not respond to other treatments.

Apremilast improved symptoms in patients with severe skin conditions.

Sintilimab treatment caused hair loss but led to complete tumor remission.

Anifrolumab improves quality of life and reduces steroid use in lupus patients.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.

Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.

Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.

Dutasteride may help reduce brain inflammation and improve cognition.

Dimethyl fumarate speeds up wound healing in IL-36Ra deficient mice by reducing NET formation and oxidative stress.

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

Secukinumab reduces immune activity in hidradenitis suppurativa skin.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

Anifrolumab effectively improved symptoms and reduced steroid use in Japanese patients with systemic lupus erythematosus.

Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.